DDInter770 DDInter178
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Fluvoxamine {u} (Compound) resembles {v} (Compound) Ridogrel
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP3A4
Fluvoxamine {u} (Compound) upregulates {v} (Gene) CCNA1
Fluvoxamine {u} (Compound) palliates {v} (Disease) endogenous depression
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Accommodation disorder
Fluvoxamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tenecteplase
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Phenylpropanolamine
Fluvoxamine (Compound) resembles Ridogrel (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene)
Fluvoxamine (Compound) upregulates CCNA1 (Gene)
Fluvoxamine (Compound) palliates endogenous depression (Disease)
Fluvoxamine (Compound) downregulates HERPUD1 (Gene)
Fluvoxamine (Compound) causes Accommodation disorder (Side Effect)
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase
Fluvoxamine may lead to a major life threatening interaction when taken with Phenylpropanolamine